ATOSNasdaqPharmaceutical PreparationsFiscal year ends December 31
ATOSSA THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$2.56−0.35 (-12.03%)
Close on Oct 19, 2026
- Market cap
- $22.81M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
–
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -186.3% | -88.4% | -62.7% | |
| Return on assets | -122.6% | -62.2% | -56.1% | |
| Current ratio | 3.11 | 2.73 | 5.53 | |
| Diluted shares | 0M | 0M | 9M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Atossa Therapeutics generated $108.97M from operations and spent $1.57M on capital expenditure, dividends and share buybacks. 6% of that went back into the business.
Generated
$108.97M
Used
$1.57M
Capital expenditure$92.00K6%Dividends$00%Share buybacks$1.48M94%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$34.77M
- Cash generatingOperating cash flow above zero-$29.76M
- Return on assets improvedROA up on the prior year-26.5% → -45.5%
- Earnings backed by cashOperating cash flow above net income-$29.76M vs -$34.77M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose14.99 → 5.53
- No dilutionShare count did not rise8M → 9M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –